Navigation Links
Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis
Date:11/7/2007

Golimumab Achieved Primary and Major Secondary Endpoints in the Largest

Phase 3 Biologic Trial Completed to Date in Psoriatic Arthritis

BOSTON, Nov. 7 /PRNewswire/ -- Patients with active psoriatic arthritis receiving monthly subcutaneous (SC) injections of golimumab (CNTO 148) experienced significant and sustained improvements in the joint and skin manifestations of the disease, according to findings from the largest Phase 3 biologic study ever completed in subjects with psoriatic arthritis. Findings presented at the American College of Rheumatology (ACR) Annual Scientific Meeting showed that at week 14 of the 405-patient study in subjects with active psoriatic arthritis, 51 percent of patients receiving golimumab 50 mg and 45 percent of patients receiving golimumab 100 mg experienced at least 20 percent improvement in arthritis signs and symptoms (ACR 20) compared with 9 percent of patients receiving placebo (P < 0.001 for both comparisons). Golimumab-treated patients maintained significant improvements in arthritis through week 24 and also showed substantial and sustained improvements in skin and nail psoriatic disease (as measured by a 75 percent reduction in Psoriasis Area and Severity Index [PASI 75] in patients with baseline body surface area with psoriasis of at least three percent, and the Nail Psoriasis Severity Index [NAPSI]).

Golimumab, Centocor Inc. and Schering-Plough Corporation's next-generation human anti-tumor necrosis factor (TNF)-alpha monoclonal antibody, is currently in the most comprehensive Phase 3 development program to date for an anti-TNF- alpha biologic therapy. With ongoing studies for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, golimumab is being studied as a monthly SC injection and an every twelve-week intravenous (IV) infusion (approximately 30-minutes) therapy.

"The availability of treatments that target TNF-alpha have dramatically changed rheumatologists' ap
'/>"/>

SOURCE Centocor Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... 2015   BioClinica®, Inc ., a specialty ... that it has acquired a leading global patient ... (Medici).  The acquisition includes affiliates MediciGlobal , ... provides a lost-to-follow-up patient locate service ( L2FU®) ... Medici, BioClinica will offer pharmaceutical companies ...
(Date:7/6/2015)... Research and Markets( http://www.researchandmarkets.com/research/45v9b3/urinary_slings ) has ... in the US 2015-2019" report to their offering. ... in the US to grow at a CAGR of ... covers the present scenario and the growth prospects of ... period 2015-2019. To calculate the market size, the report ...
(Date:7/6/2015)... 6, 2015 Array BioPharma,s (NASDAQ:   ... past weekend at the 2015 ESMO World Congress ... the meeting, data were shared from a Phase ... randomized Phase 2 expansion of that trial testing ... inhibitor, with or without the addition of alpelisib ...
Breaking Medicine Technology:BioClinica Acquires MediciGroup 2BioClinica Acquires MediciGroup 3United States Urinary Slings Market 2015-2019 - Vaginal Slings (TVT, TOT, and Single-incision) & Male Slings (Artificial Urinary Sphincters) 2Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 2Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 3Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 4
... Dec. 29 Spectranetics Corporation, a medical device manufacturer, ... in civil damages plus a $100,000 forfeiture to resolve ... The claims arise from allegations that the company illegally ... for use in patients, conducted a clinical study in ...
... , , , , ENGLEWOOD, Colo., Dec. ... device technology for the safe handling, packaging and administration ... its culture of safety initiative for today,s health-system pharmacies. ... in Pharmacy: Lessons Learned," features an industry-leading panel of ...
Cached Medicine Technology:Colorado-Based Spectranetics Corporation to Pay $5 Million to Resolve Allegations Relating to its Medical Devices 2Baxa Corporation to Sponsor Free Culture of Safety Webinar 2Baxa Corporation to Sponsor Free Culture of Safety Webinar 3
(Date:7/6/2015)... ... ... World renowned Los Angeles facial plastic surgeon , Dr. Paul Nassif, ... solutions. Individuals that want to make multiple changes to their facial appearance are able ... of their needs. , "Anytime I see an opportunity to change the life ...
(Date:7/6/2015)... Pompano Beach, Florida (PRWEB) , ... July 06, ... ... call center solutions, announced today that Randstad Technologies selected Aspect Software Unified IP ... provider in the United States, selected Aspect Unified IP as its future call ...
(Date:7/6/2015)... London, United Kingdom (PRWEB) , ... July 06, 2015 , ... ... Guide app could help. More than 29 million Americans have diabetes, the majority of ... addition, 86 million U.S. adults or more than one in three, have prediabetes (abnormally ...
(Date:7/6/2015)... ... July 06, 2015 , ... The Path of Least ... the economic transformation associated with the U.S. economy over the past 40 years. The ... its use. In many ways, the book is a time capsule that chronicles the ...
(Date:7/5/2015)... ... July 06, 2015 , ... City Sports, the Boston-based specialty sporting goods ... training clinics for first-time triathletes this summer with ethos, the owner and operator of ... July 9, at 6:00 p.m. at the North End Greenway. The event will help ...
Breaking Medicine News(10 mins):Health News:Los Angeles Plastic Surgeon, Dr. Paul Nassif, is Now Offering Comprehensive Facial Plastic Surgery Procedures 2Health News:Aspect Software Unified IP, Hosted by Promero, Selected by Randstad Technologies 2Health News:Aspect Software Unified IP, Hosted by Promero, Selected by Randstad Technologies 3Health News:115 Million in the U.S. could beat diabetes with the help of a new app 2Health News:New Book Brings Reveals The Repercussions Associated With The Global Economy 2Health News:Sporting Goods Retailer City Sports Renews Partnership with Boston Triathlon 2Health News:Sporting Goods Retailer City Sports Renews Partnership with Boston Triathlon 3
... Sonoma is known for delicious food, great,wine and ... known for inventive,beef recipes. The 28th National Beef ... peak of the area,s beautiful harvest season to host ... Home cooks nationwide,and local professional restaurant chefs working in ...
... Alternext US: ADL), a vertically integrated pharmaceutical company with ... has revised its 2009 Performance and Equity Incentive Compensation ... of the Plan, AMDL has transitioned from a "discretionary ... and cash incentive plan. Incentives are based on ...
... 8 Allscripts,announced today that Excela Health, a ... the Allscripts Enterprise Electronic Health,Record (EHR) for the ... Excela Health,Physician Practices (EHPP). , ... Excela Health, serving residents ...
... Study included nearly 57,000 women who had been followed ... News) -- Hormone therapy may lower a woman,s risk ... taking the hormones. , This new finding, published in ... Prevention , further complicates an already murky picture of ...
... Inc. launches its,next generation P-55C dye-sublimation thermal disc printer, ... CES Show at,the Las Vegas Convention Center, January 8-11, ... can be integrated with 3 TEAC Autoprinter,configurations, TEAC AL-220S, ... AL550S, customers can print up to 68 discs per ...
... REDWOOD CITY, Calif., Jan. 8 Genomic Health,Inc. (Nasdaq: ... Kimberly J. Popovits as,chief executive officer. Formerly president ... CEO of Genomic Health. In addition, G.,Bradley Cole ... continue,to serve as the company,s chief financial officer, reporting ...
Cached Medicine News:Health News:28th National Beef Cook-Off(R) Seeks 'Sonoma-Style' Recipe Entries 2Health News:28th National Beef Cook-Off(R) Seeks 'Sonoma-Style' Recipe Entries 3Health News:AMDL, Inc. Completes Revision of Performance & Equity Incentive Compensation Plan 2Health News:Excela Health Selects Allscripts Electronic Health Record for Physicians 2Health News:Excela Health Selects Allscripts Electronic Health Record for Physicians 3Health News:Excela Health Selects Allscripts Electronic Health Record for Physicians 4Health News:Excela Health Selects Allscripts Electronic Health Record for Physicians 5Health News:Hormone Therapy May Cut Colorectal Cancer Risk 2Health News:TEAC America Launches its Next Generation P-55C Printer, World's Fastest Dye-Sublimation Disc Printer 2Health News:Genomic Health Announces Management Changes and New Responsibilities 2Health News:Genomic Health Announces Management Changes and New Responsibilities 3Health News:Genomic Health Announces Management Changes and New Responsibilities 4
... the HI VISION 8500 diagnostic ultrasound ... user-oriented operation for exceptional imaging and ... consists of advanced techniques for image ... multi-angle spatial compounding, wideband pulse-inversion, tissue ...
... EG-3630U incorporates a 2.4mm channel within a ... all electronic convex linear array ultrasound image ... for improved lateral resolution, and a 7.5 ... The color & pulsed doppler allows ...
... The advanced features of the ELECTRA ... operational costs with extended walkaway capabilities. This ... performs APTT, PT, fibrinogen and factor assays ... an integrated barcode reader and automatic preparation ...
... ACL 7000 coagulation analyzer is the ... needs a full range of testing ... have access to a broad test ... Plus, you'll benefit from an easy-to-use, ...
Medicine Products: